Gilead Sciences

$73 per share – $84 per share / growth in 15%

Shares of the company began to grow in hope of development of Remdesivir, a potential antiviral drug for the coronavirus. The vaccine was being developed in a team led by Czech Tomáš Cihlář. Even though the vaccine failed in its first clinical trial, positive effects in treatment of patients infected by COVID-19 have been demonstrated. The vaccine does speed up recovery from COVID-19 infection and reduces mortality rate.